Potential to become the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns

Read the original post:
Vericel Announces FDA Approval of NexoBrid for the Treatment of Severe Thermal Burns in Adults

PRESS RELEASE

View original post here:
AB Science has received approval from the U.S. Food and Drug Administration (FDA) to initiate the confirmatory Phase 3 study with masitinib in the...

New Director Brings Extensive Experience to Poise the Company for Growth New Director Brings Extensive Experience to Poise the Company for Growth

More here:
Neuronetics Announces Appointment of Joseph H. Capper to its Board of Directors

Potential to become the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns

See the original post here:
MediWound Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults

LONDON, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (“Tiziana”, NASDAQ: TLSA), a biotechnology company enabling breakthrough CNS immunomodulation approaches to enhance the functionality of Treg-based therapies, today announced its interim results for the six months ended 30 June 2022.

Read the original:
Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) - Updated Interim Results for the Six Months Ended 30 June 2022

NEW YORK, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Following the formation of Mayflower Bioventures, a cell and gene therapy accelerator stood up from Hibiscus BioVentures and Mayo Clinic, comes the launch of their first start-up, Primera Therapeutics, Inc. (Primera). Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its gene editing platform to deliver life-saving cell and gene therapies, and Primera announced today the execution of a Collaboration Agreement under which the Parties will work collaboratively to edit mutations in the mitochondrial DNA (mtDNA) in vivo to treat the root cause of associated diseases.

See the original post here:
Mayflower Bioventures Launches its First Spin-Out, Primera Therapeutics, in Strategic Collaboration with Cellectis to Develop a Gene Editing Platform...

LONDON and NEW YORK, Dec. 30, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO, NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company developing OK-101 to treat Dry Eye Disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announces its interim results for the six months ended 30 September 2022.

See the original post:
OKYO Pharma Limited - Interim Results for the Six Months Ending 30 September 2022

WINNIPEG, Manitoba, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces that it has reached an agreement to obtain loans (the “Loans”) in the aggregate amount of $2,000,000 from two lenders (the “Lenders”). The Loans will bear interest at 12% per annum and mature on March 31, 2024.

Excerpt from:
Kane Biotech Announces Loan Transaction

WATERTOWN, Mass., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (“Disc”), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that its previously-announced merger with Gemini Therapeutics, Inc. (“Gemini”) closed on December 29, 2022, following the approval of Gemini shareholders. The combined company, focused on advancing Disc’s pipeline of hematology programs, will operate under the name Disc Medicine, Inc. and its shares will commence trading on a 1-10 reverse split adjusted basis effective with the open of business on December 30, 2022 on the Nasdaq Global Market under the ticker symbol IRON.

Read the original post:
Disc Medicine Announces Completion of Merger with Gemini Therapeutics

JERUSALEM, Dec. 30, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products for the treatment of infectious and autoimmune diseases, today published a letter from its CEO, Amir Reichman, addressing 2022 accomplishments, successful preclinical trial results of the inhaled COVID-19 NanoAb therapy as well as recent financing activities to support 2023 objectives. The letter reads as follows:

See more here:
BiondVax CEO Issues Letter to Shareholders

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS

More here:
Avicanna Announces Organizational Change in Avicanna LATAM S.A.S

The Phase 2 multicenter, open-label combination trial builds upon the promising results of monotherapeutic activity of ONC-392 seen in previous clinical trial

More here:
OncoC4 Announces First Patient Dosed in PRESERVE-004, a Phase 2 Clinical Trial of ONC-392 in Combination with KEYTRUDA® (Pembrolizumab) in Patients...

Cash runway now expected to extend into at least 2025 as a result of revised timeline of global Phase 3 program of CBP-201 in atopic dermatitis (AD); Longer cash runway permits continued evaluation of potential partnership opportunities to advance the global AD Phase 3 program

Read more here:
Connect Biopharma Provides Business and Clinical Development Program Update

SAN DIEGO, Dec. 30, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will effect a reverse stock split of all outstanding shares of the company’s common stock at a ratio of 25 to 1. The company expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Global Market as of the commencement of trading on January 3, 2023.

Visit link:
Biora Therapeutics Announces Reverse Stock Split

Saint-Herblain (France), December 30, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further heterologous booster data from an exploratory, small clinical study for its inactivated COVID-19 vaccine, VLA2001.

Excerpt from:
Valneva Reports Further Heterologous Booster Data for its inactivated COVID-19 vaccine

The Phase 2 multicenter, open-label combination trial builds upon the promising results of monotherapeutic activity of ONC-392 seen in previous clinical trial The Phase 2 multicenter, open-label combination trial builds upon the promising results of monotherapeutic activity of ONC-392 seen in previous clinical trial

Link:
UPDATE - OncoC4 Announces First Patient Dosed in PRESERVE-004, a Phase 2 Clinical Trial of ONC-392 in Combination with KEYTRUDA® (Pembrolizumab) in...

Company announcement – No. 58 / 2022

More here:
Total number of shares and voting rights in Zealand Pharma at December 30, 2022

CAMBRIDGE, United Kingdom, Dec. 31, 2022 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, UK, congratulates Harren Jhoti, PhD, FRS, FMedSci, its co-founder, President and CEO on being honoured in the 2023 King’s New Year Honours list. Dr. Jhoti has been made an Officer of the Order of the British Empire (OBE) for services to Cancer Research and Drug Discovery.

Read more:
Astex Co-founder and CEO Harren Jhoti Awarded OBE in the King’s New Year Honours

VANCOUVER, British Columbia, Dec. 30, 2022 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) announces the voting results from its Annual General Meeting of Shareholders (the "Meeting"), held in Vancouver, British Columbia on December 30, 2022. The total number of shares represented by shareholders present in person and by proxy at the Meeting was 23,664,112, representing 9.39% of Sirona's issued and outstanding Common Shares.

Read this article:
Sirona Biochem Announces 2022 Annual Meeting Results

Media ReleaseCOPENHAGEN, Denmark; January 2, 2023Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 41st?Annual J.P. Morgan Healthcare Conference in San Francisco at 9:00 AM PST / 12:00 PM EST / 6:00 PM CET on January 11, 2023.?The live and archived webcast of the presentation will be available on Genmab’s website at?https://ir.genmab.com/events-and-presentations#content.

Go here to see the original:
Genmab to Present at the 41st Annual J.P. Morgan Healthcare Conference